cenersen + idarubicin + cytarabine

Cenersen + idarubicin + cytarabine is a **combination regimen** evaluated for the treatment of acute myeloid leukemia (AML), especially in patients with relapsed or refractory disease. **Cenersen** is an antisense oligonucleotide targeting p53 mRNA, designed to inhibit p53 protein synthesis and thereby sensitize AML stem cells to DNA-damaging agents[1][2][10]. **Idarubicin** is an anthracycline chemotherapy agent that intercalates into DNA, inhibiting topoisomerase II and causing DNA breaks, leading to apoptosis. **Cytarabine** is a pyrimidine nucleoside analog that gets incorporated into DNA, inhibiting DNA polymerase and preventing DNA synthesis. The combination aims to increase leukemia cell sensitivity to chemotherapy, leveraging cenersen’s molecular priming to potentially boost the cytotoxic effects of idarubicin and cytarabine. Trials indicate the regimen may improve response rates in this high‐risk patient population, with manageable toxicity and safety profiles similar to chemotherapy alone[1][2][10].

Brand names

None known specific combination brand name

Other names

p53 antisense oligonucleotide + idarubicin + cytarabine